Through Advancements In Natural Science, Medicine, And Genomics, we aim to improve the lives of patients who suffer from cancer and other debilitating diseases.
Diverse Biotech, Inc is an innovative drug-discovery & biopharmaceutical research company committed to discovering and developing novel therapies from its proprietary conjugate drug synthesis Platform.
The company originated from oncologists adding cannabinoid therapy to standard of care treatment for cancer patients and reporting significant benefits.
By utilizing strategic hiring, we brought on lead scientists and chemical engineers to improve the cannabinoid molecule. We have succeeded in creating a novel new class of cancer fighting drugs, never-before existing in nature. Molecules that utilize the cannabinoid molecule structure in order to attack cancer at its core.
Based on the research results, Diverse Biotech has taken the technology to the next level and put an experienced Executive Leadership Team in place to take the company forward.
Discovered in 1979, the
endocannabinoid system is a complex
system of tissue receptors which
interact with natural cannabinoids to
keep the human body in optimal health.
Once the endocannabinoid system
is activated, it sends signals to the
brain and tissues eliciting many effects
which take place through activation
of different receptor types (CB1, CB2,
TRPV1, & TRPV2).
Impacts many systems and organs in
the human body.
